RVX.TO

Resverlogix Corp. [RVX.TO] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RVX.TO Stock Summary

In the News

RVX.TO Financial details

Company Rating
-
Market Cap
14.97M
Income
-7.67M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
19
Optionable
No
Shortable
Yes
Earnings
03 Jul 2024
P/E
-1.72
Forward P/E
-
PEG
0.33
P/S
-
P/B
-0.18
P/C
-
P/FCF
37.23
Quick Ratio
0.01
Current Ratio
0.11
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.05
EPS next Y
-
EPS next Q
-
EPS this Y
-85.8%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
10.07%
-
-
-
-
SMA20
-20%
SMA50
-20%
SMA100
-33.33%
Inst Own
-
Inst Trans
-
ROA
-98%
ROE
15%
ROC
0.28%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.055-0.18
52W High
-
52W Low
-
RSI
54.22
Rel Volume
0.18
Avg Volume
32.48K
Volume
6K
Perf Week
12.5%
Perf Month
-10%
Perf Quarter
-30.77%
Perf Half Y
-30.77%
-
-
-
-
Beta
0.725
-
-
Volatility
0%, 0%
Prev Close
12.5%
Price
0.045
Change
12.5%

Something similar

Top by Market Cap
JPM
APC.DE
V
LLY
VTI
Same Sector
AVTBF
PRTC
2696.HK
4540.T
7649.T
Same Price Range
TOM.L
8425.HK
8036.HK
8362.HK
ALNLF.PA
Similar Market Cap
CBSX.DE
GRNQ
MTEK
XMR.ST
ALTHE.PA

Company Profile

Healthcare Biotechnology
  • Volume Average 32.48K
  • Market Capitalization 14.97M
  • Employee 19
  • CEO Mr. Donald J. McCaffrey
  • Headquarters Calgary,AB,CA
  • IPO Date 2004-05-07
  • Website https://www.resverlogix.com

Resverlogix Corp., a late-stage clinical biotechnology company, develops therapeutics for disease states with high unmet medical needs. It is developing apabetalone (RVX-208), a small molecule selective bromodomain and extra-terminal inhibitor that is in Phase III clinical trial for patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, end-stage renal disease, and neurodegenerative diseases. Resverlogix Corp. has a partnership with Eversana Life Science Services, LLC to support the pending launch of the commercialization of apabetalone for Covid-19 in the United States and Canada. The company is headquartered in Calgary, Canada.